S100 beta is associated with cognitive impairment in childhood-onset systemic lupus erythematosus patients

Autor(es)

Lapa, A. T. ; Postal, M. ; Sinicato, N. A. ; Bellini, B. S. ; Fernandes, P. T. ; Marini, R. ; Appenzeller, S.

• Tipo de documento: Artigo Científico
• Fonte: Lupus; v. 26, n. 5, SI, p. 478-483, APR 2017.
• Citações Web of Science: 4

Resumo

Objective: To investigate serologic S100 beta protein levels in childhood-onset SLE patients (cSLE) and to elucidate their association with disease activity and neuropsychiatric (NP) manifestations. Methods: We included 71 cSLE patients (67 females; median age 18 years; range 9-37 and 53 (47 females; median age of 20 years; range 6-29) age and sex matched healthy controls. Neurological manifestations were analysed according to the American College of Rheumatology (ACR) criteria. Cognitive evaluation was performed in all participants using Wechsler Intelligence Scale for Children (WISC-III) and Wechsler Adult Intelligence Scale (WAIS), according to age, and validated in Portuguese. SLE patients were further assessed for clinical and laboratory SLE manifestations, disease activity (SLE Disease Activity Index (SLEDAI)), damage (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)) and current drug exposures. Sera S100 beta protein levels were measured by enzyme-linked immunosorbent assay using commercial kits. Results: The median S100 beta protein level was 116.55 pg/mL (range 1.53-468.50) in cSLE and 54.98 pg/mL (range 0.69-181.00) in healthy controls (p<0.001). An association was observed between S100 beta protein and NP manifestations (p = 0.03). The S100 beta protein levels was associated with cognitive impairment in cSLE patients (p = 0.006). Conclusions: S100 beta protein levels are increased in cSLE with cognitive impairment. S100 beta may be considered a potential biomarker that underlies central nervous system (CNS) dysfunction, especially cognitive impairment. (AU)

• Processo FAPESP: 11/03788-2 - Avaliação longitudinal das interleucinas 4, 6, 10 e 12, do interferon gama e fator de necrose tumoral alfa e associações clínicas e laboratoriais em pacientes com lúpus eritematoso sistêmico
• Beneficiário: Mariana Postal Zink de Souza
• Linha de fomento: Bolsas no Brasil - Doutorado
• Processo FAPESP: 08/02917-0 - Determinação de marcadores séricos e do líquor associados a alterações estruturais e funcionais do sistema nervoso central no lúpus eritematoso sistêmico
• Beneficiário: Simone Appenzeller
• Linha de fomento: Auxílio à Pesquisa - Apoio a Jovens Pesquisadores